FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983604922> ?p ?o ?g. }

• W2983604922 endingPage "4637" @default.
• W2983604922 startingPage "4637" @default.
• W2983604922 abstract "Introduction 'X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection, and neoplasia' (XMEN) disease is a primary immunodeficiency disease caused by loss-of-function mutations in the MAGT1 gene encoding for the magnesium transporter 1. This leads to the absence of expression of the Natural-Killer Group 2, member D (NKG2D) receptor in natural killer (NK) and CD8+ T cells, which is essential for their antiviral and antitumoral cytotoxic activity. In consequence, XMEN patients develop chronic EBV infections and EBV-related lymphoproliferative disorders. Allogeneic bone marrow transplant has been associated with significant mortality, and there are no other effective treatments. In that context, we aimed at developing two complementary approaches to treat XMEN patients: 1) Adoptive transfer of XMEN T/NK cells corrected by transient mRNA therapy or longer-lasting gene editing therapy in order to control infections, and 2) Transplantation of gene-edited CD34+ cells in order to permanently restore production of functional immune cells. Material and methods CD34+ cells and PBMCs were collected from XMEN patients and healthy donors (HD) (NIH Protocol 94-I-073). For mRNA therapy, we expanded T cells with anti-CD3/anti-CD28 beads in RPMI + 10% serum supplemented with 200 IU/mL IL2 for 5-7 days and NK cells with 100 IU/mL IL2 and 10 ng/mL IL15 in culture with K562-mb15-41BBL for 10-15 days. Both XMEN T and NK cells were electroporated (EP) with MAGT1 mRNA and cultured for up to 28 days. For gene editing, XMEN CD34+ or stimulated T cells were electroporated with Cas9 mRNA and sgRNA; a rAAV6 donor encoding for the codon-optimized MAGT1 cDNA was added after EP. Two days post-EP, CD34+ cells were differentiated into NK cells for 35 days in vitro. Results MAGT1 mRNA-based therapy. We first showed a restored MAGT1 expression by western blot at 6h and 24h post-EP of the MAGT1 mRNA. In consequence, NKG2D expression analyzed by flow cytometry was restored in expanded CD8+ T and NK cells starting within the 6h post-EP (20-40%), with a peak at 48h (>85%) and a progressive decrease of the expression over time (still 40% and 75%, respectively, of CD8+ T and NK cells of cells at day 14 post-EP respectively). The cytotoxic activity of mRNA-corrected XMEN NK cells was analyzed by culture with K562 target cells at several effector:target (E:T) ratios and shown to be restored at a level similar to HD NK cells (mRNA-treated: 66.7% ±5.8%; HD: 67.8% ±5.9% at E:T 2:1 ratio) compared to untreated cells (49.0% ±7.2%) (Fig 1a). Anticipating the potential use of these cells for repeated infusions as a treatment modality to control infections, we demonstrated that MAGT1 mRNA-corrected CD8+ T and NK cells that have been cryopreserved and thawed exhibit the same NKG2D expression kinetics following thaw and culture. Gene editing therapy. XMEN CD34+ cells electroporated with Cas9 mRNA and a sgRNA targeting exon 1 of MAGT1 gene showed an in vitro average integration rate of the MAGT1 cDNA AAV donor of 35.6% (range: 33.8-41.9%). The NKG2D expression in AAV-treated CD34+-derived NK cells was approximatively of 23% (range: 14.2-27.9%). Interestingly, their cytotoxic activity was similar to the level of NKG2D expression (23.1% ±4.3%), significantly higher than in untreated cells (9.7% ±2.8%) (Fig 1b). Similar rates of targeted integration and NKG2D expression were also obtained in AAV-treated CD8+ T cells. Conclusion For the first time, we demonstrate the efficiency of two approaches for development of potential cell therapy treatments of XMEN patients. MAGT1 mRNA electroporation can restore efficient transient expression of NKG2D in CD8+ T and NK cells, thus fully restoring the cytotoxic activity of NK cells. In addition, cells electroporated with MAGT1 mRNA can be cryopreserved, thus allowing repeated infusions. In parallel, we showed that efficient targeted insertion can be achieved in CD8+ T cells and CD34+ cells by using an AAV donor although the level of NKG2D expression is lower. Optimizations are currently ongoing in order to reach higher levels of correction. Both approaches could be combined in order to propose a new therapeutic strategy for the treatment of XMEN patients: repetitive adoptive transfer of mRNA-corrected autologous T/NK cells for the prevention or control of intractable infections, and transplantation of gene-edited CD34+ cells for the definitive treatment of these patients. Disclosures Meis: CELLSCRIPT, LLC: Employment. Li:MaxCyte, Inc: Employment. Allen:MaxCyte, Inc: Employment. Clark:CELLSCRIPT, LLC: Employment. Dahl:CELLSCRIPT, LLC: Other: Owner and officer." @default.
• W2983604922 created "2019-11-22" @default.
• W2983604922 creator A5002789970 @default.
• W2983604922 creator A5008278559 @default.
• W2983604922 creator A5023915503 @default.
• W2983604922 creator A5028051194 @default.
• W2983604922 creator A5029419417 @default.
• W2983604922 creator A5043346347 @default.
• W2983604922 creator A5057437192 @default.
• W2983604922 creator A5060636006 @default.
• W2983604922 creator A5061934168 @default.
• W2983604922 creator A5066402410 @default.
• W2983604922 creator A5070549026 @default.
• W2983604922 creator A5071545468 @default.
• W2983604922 creator A5072201310 @default.
• W2983604922 creator A5079729144 @default.
• W2983604922 creator A5081737757 @default.
• W2983604922 creator A5086044002 @default.
• W2983604922 date "2019-11-13" @default.
• W2983604922 modified "2023-09-26" @default.
• W2983604922 title "Gene Editing and mRNA-Based Therapy: Two Complementary Therapeutic Approaches for the Treatment of Patients with Xmen Disease" @default.
• W2983604922 doi "https://doi.org/10.1182/blood-2019-129062" @default.
• W2983604922 hasPublicationYear "2019" @default.
• W2983604922 type Work @default.
• W2983604922 sameAs 2983604922 @default.
• W2983604922 citedByCount "0" @default.
• W2983604922 crossrefType "journal-article" @default.
• W2983604922 hasAuthorship W2983604922A5002789970 @default.
• W2983604922 hasAuthorship W2983604922A5008278559 @default.
• W2983604922 hasAuthorship W2983604922A5023915503 @default.
• W2983604922 hasAuthorship W2983604922A5028051194 @default.
• W2983604922 hasAuthorship W2983604922A5029419417 @default.
• W2983604922 hasAuthorship W2983604922A5043346347 @default.
• W2983604922 hasAuthorship W2983604922A5057437192 @default.
• W2983604922 hasAuthorship W2983604922A5060636006 @default.
• W2983604922 hasAuthorship W2983604922A5061934168 @default.
• W2983604922 hasAuthorship W2983604922A5066402410 @default.
• W2983604922 hasAuthorship W2983604922A5070549026 @default.
• W2983604922 hasAuthorship W2983604922A5071545468 @default.
• W2983604922 hasAuthorship W2983604922A5072201310 @default.
• W2983604922 hasAuthorship W2983604922A5079729144 @default.
• W2983604922 hasAuthorship W2983604922A5081737757 @default.
• W2983604922 hasAuthorship W2983604922A5086044002 @default.
• W2983604922 hasConcept C104317684 @default.
• W2983604922 hasConcept C111599444 @default.
• W2983604922 hasConcept C126322002 @default.
• W2983604922 hasConcept C151730666 @default.
• W2983604922 hasConcept C154317977 @default.
• W2983604922 hasConcept C167672396 @default.
• W2983604922 hasConcept C202751555 @default.
• W2983604922 hasConcept C203014093 @default.
• W2983604922 hasConcept C2778867473 @default.
• W2983604922 hasConcept C2779343474 @default.
• W2983604922 hasConcept C2780007613 @default.
• W2983604922 hasConcept C2911091166 @default.
• W2983604922 hasConcept C502942594 @default.
• W2983604922 hasConcept C55493867 @default.
• W2983604922 hasConcept C71924100 @default.
• W2983604922 hasConcept C86803240 @default.
• W2983604922 hasConcept C8891405 @default.
• W2983604922 hasConceptScore W2983604922C104317684 @default.
• W2983604922 hasConceptScore W2983604922C111599444 @default.
• W2983604922 hasConceptScore W2983604922C126322002 @default.
• W2983604922 hasConceptScore W2983604922C151730666 @default.
• W2983604922 hasConceptScore W2983604922C154317977 @default.
• W2983604922 hasConceptScore W2983604922C167672396 @default.
• W2983604922 hasConceptScore W2983604922C202751555 @default.
• W2983604922 hasConceptScore W2983604922C203014093 @default.
• W2983604922 hasConceptScore W2983604922C2778867473 @default.
• W2983604922 hasConceptScore W2983604922C2779343474 @default.
• W2983604922 hasConceptScore W2983604922C2780007613 @default.
• W2983604922 hasConceptScore W2983604922C2911091166 @default.
• W2983604922 hasConceptScore W2983604922C502942594 @default.
• W2983604922 hasConceptScore W2983604922C55493867 @default.
• W2983604922 hasConceptScore W2983604922C71924100 @default.
• W2983604922 hasConceptScore W2983604922C86803240 @default.
• W2983604922 hasConceptScore W2983604922C8891405 @default.
• W2983604922 hasIssue "Supplement_1" @default.
• W2983604922 hasLocation W29836049221 @default.
• W2983604922 hasOpenAccess W2983604922 @default.
• W2983604922 hasPrimaryLocation W29836049221 @default.
• W2983604922 hasRelatedWork W2018916009 @default.
• W2983604922 hasRelatedWork W2054101033 @default.
• W2983604922 hasRelatedWork W2112065900 @default.
• W2983604922 hasRelatedWork W2164587311 @default.
• W2983604922 hasRelatedWork W2327592239 @default.
• W2983604922 hasRelatedWork W2393196597 @default.
• W2983604922 hasRelatedWork W2981642747 @default.
• W2983604922 hasRelatedWork W3145520151 @default.
• W2983604922 hasRelatedWork W4308988935 @default.
• W2983604922 hasRelatedWork W4320717881 @default.
• W2983604922 hasVolume "134" @default.
• W2983604922 isParatext "false" @default.
• W2983604922 isRetracted "false" @default.
• W2983604922 magId "2983604922" @default.
• W2983604922 workType "article" @default.